Get started
Author

Anna C. Dusenbery

Observed names: Anna C Dusenbery, Anna Dusenbery
ORCID: 0000-0002-3736-7995
Observed ORCID: 0000-0002-3736-7995
OpenAlex ID: A5002282387
MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors
2021 · Anna C. Dusenbery, Joseph L. Maniaci, et al. · The American Journal of Surgical Pathology · 53
Emerging biomarkers in ovarian granulosa cell tumors
2019 · Anne M Mills, Zachary Chinn, et al. · International Journal of Gynecological Cancer · 24
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al. · Cancer Research Communications · 12
PDF
Global Health Education in Pathology Residency
2020 · Ashley K Volaric, Sara L Zadeh, et al. · American Journal of Clinical Pathology · 6
Chromosomal microarray analysis of benign mesenchymal tumors with RB1 deletion
2020 · Anna C. Dusenbery, Jonathan J. Davick, et al. · Human Pathology · 6
RNA fusion transcript panel identifies diverse repertoire of fusions in adult glioma patients with therapeutic implications
2023 · Shawn Kothari, Anna C Dusenbery, et al. · Neuro-Oncology Practice · 3
PDF
Cytodiagnosis and protein typing of amyloid from a vitreous washing: initial diagnostic workup of hereditary amyloidosis
2020 · Joseph D. Coppock, Anna C. Dusenbery, et al. · Journal of the American Society of Cytopathology · 2
Pleomorphic Sarcoma Mimicking a Chronic Hematoma, Ultimately Diagnosed by Angiography
2019 · Timothy C. Huber, Anna Dusenbery, et al. · Journal of Vascular and Interventional Radiology · 1
PP01.106 Validation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab Monotherapy Benefit in First Line (1L) Non-small cell lung cancer (NSCLC)
2024 · Brandi Oakley, Justin Moon, et al. · Journal of Thoracic Oncology
PDF
FIGURE 4 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Data S2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Table S7 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Figure S1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
PDF
Supplementary Figure S6 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Figure S2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Data S1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 4 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Table S2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Figure S8 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Figure S4 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
PDF
Supplementary Table S11 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
PDF
Supplementary Table S3 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Works count: 78
Citation count: 107
H-index: 5
I10-index: 3
Year
Topic
Type